Zhang Financial LLC Buys 1,424 Shares of Amgen Inc. $AMGN

Zhang Financial LLC increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 8.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,358 shares of the medical research company’s stock after acquiring an additional 1,424 shares during the quarter. Zhang Financial LLC’s holdings in Amgen were worth $4,899,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Prestige Wealth Management Group LLC grew its stake in Amgen by 6.4% in the third quarter. Prestige Wealth Management Group LLC now owns 1,455 shares of the medical research company’s stock valued at $411,000 after acquiring an additional 88 shares during the period. Mufg Securities Americas Inc. raised its position in shares of Amgen by 21.8% during the third quarter. Mufg Securities Americas Inc. now owns 14,518 shares of the medical research company’s stock worth $4,097,000 after purchasing an additional 2,601 shares during the period. First Financial Bankshares Inc lifted its holdings in shares of Amgen by 0.7% during the 3rd quarter. First Financial Bankshares Inc now owns 220,422 shares of the medical research company’s stock valued at $62,203,000 after purchasing an additional 1,552 shares in the last quarter. Compound Planning Inc. increased its stake in Amgen by 8.4% during the 3rd quarter. Compound Planning Inc. now owns 6,840 shares of the medical research company’s stock worth $1,930,000 after purchasing an additional 529 shares in the last quarter. Finally, Portland Global Advisors LLC raised its holdings in Amgen by 1.2% during the 3rd quarter. Portland Global Advisors LLC now owns 24,065 shares of the medical research company’s stock worth $6,791,000 after buying an additional 287 shares during the period. Institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on AMGN shares. BMO Capital Markets raised their price objective on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. UBS Group lifted their price target on Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Rothschild & Co Redburn boosted their price target on Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a report on Wednesday, February 18th. Cantor Fitzgerald upped their price objective on Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Finally, Freedom Capital lowered Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Amgen currently has a consensus rating of “Moderate Buy” and an average target price of $351.76.

Amgen Stock Up 0.9%

AMGN stock opened at $382.87 on Wednesday. The company has a market cap of $206.39 billion, a price-to-earnings ratio of 26.91, a P/E/G ratio of 3.76 and a beta of 0.46. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $385.12. The business has a 50 day moving average price of $345.41 and a two-hundred day moving average price of $317.87. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter in the prior year, the business posted $5.31 EPS. The business’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a $2.52 dividend. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.6%. Amgen’s payout ratio is 70.84%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.